




















![]()
Q1: 2026-05-14 Earnings Summary
EPS of -$1.72 misses by $0.31
|
Revenue of
$6.39M
(-92.82% Y/Y)
misses by $18.85M
REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call May 14, 2026 8:00 AM EDT
Company Participants
Patrick Christmas - Executive VP & Chief Strategy and Legal Officer
Curran Simpson - President, CEO & Director
Steve Pakola - Executive VP & Chief Medical Officer
Conference Call Participants
Aravindhan Veerapandiyan
Diana Castro
Carolina Tesi Rocha
Judah Frommer - Morgan Stanley, Research Division
Mani Foroohar - Leerink Partners LLC, Research Division
Alec Stranahan - BofA Securities, Research Division
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
Sean McCutcheon - Raymond James & Associates, Inc., Research Division
Eliana Merle - Barclays Bank PLC, Research Division
Daniil Gataulin - Chardan Capital Markets, LLC, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Yi Chen - H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Welcome, everyone, to the REGENXBIO RGX-202 Top line Pivotal Data Webcast. At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of REGENXBIO. Please go ahead.
Patrick Christmas
Executive VP & Chief Strategy and Legal Officer
Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO released pivotal top line data from the AFFINITY DUCHENNE trial of RGX-202 as well as financial and operating results for the first quarter ended March 31, 2026.
The press releases are available on our website at www.regenxbio.com. Today's webcast will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning.
Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。